Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

hepatitis E vaccine

Known as: Hep E 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Real-time stability of a hepatitis E vaccine (Hecolin®) demonstrated with potency assays and multifaceted physicochemical methods.
The first prophylactic vaccine against hepatitis E virus (HEV), Hecolin®, was licensed in China. Recombinant p239 virus-like… Expand
2016
2016
Assembly of hepatitis E vaccine by 'in situ' growth of gold clusters as nano-adjuvants: an efficient way to enhance the immune responses of vaccination.
Vaccine-based immunotherapy plays an integral role in the development of present and future clinical therapies. Despite the… Expand
2015
2015
Modeling the long-term antibody response of a hepatitis E vaccine.
BACKGROUND The first commercialized hepatitis E vaccine, HEV 239, has been shown to be safe and highly immunogenic, the… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE